Targeting islet G-protein-coupled receptors for type 2 diabetes therapy

Shanta J. Persaud; Oladapo E. Olaniru; Patricio Atanes

doi:10.1042/bio_2021_108

Targeting islet G-protein-coupled receptors for type 2 diabetes therapy

Shanta J. Persaud^*, Oladapo E. Olaniru, Patricio Atanes

^*Corresponding author for this work

Diabetes

King's College London

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

The majority of people with diabetes have type 2 diabetes (T2D), where hyperglycaemia occurs because the islet p-cells are unable to secrete enough insulin, usually in the context of insulin resistance that arises because of fat mass expansion. There are a range of pharmacotherapies in current use to treat T2D and pharmaceutical companies are actively engaged in the development of novel therapies for better glucose control. Ligands that target G-protein-coupled receptors (GPCRs) are obvious candidates because they are used successfully for a wide range of disorders and GLP-1 receptor agonists, which are a relatively recent class of diabetes therapy, have proved to be very effective in treating T2D. We provide here an overview of current successes, some drawbacks and future possibilities for GPCR-based T2D therapies.

Original language	English
Pages (from-to)	28-33
Number of pages	6
Journal	Biochemist
Volume	43
Issue number	2
DOIs	https://doi.org/10.1042/bio_2021_108
Publication status	Published - 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1042/bio_2021_108

Cite this

@article{3699a94fe4ca45caa16162bf94436ea0,

title = "Targeting islet G-protein-coupled receptors for type 2 diabetes therapy",

abstract = "The majority of people with diabetes have type 2 diabetes (T2D), where hyperglycaemia occurs because the islet p-cells are unable to secrete enough insulin, usually in the context of insulin resistance that arises because of fat mass expansion. There are a range of pharmacotherapies in current use to treat T2D and pharmaceutical companies are actively engaged in the development of novel therapies for better glucose control. Ligands that target G-protein-coupled receptors (GPCRs) are obvious candidates because they are used successfully for a wide range of disorders and GLP-1 receptor agonists, which are a relatively recent class of diabetes therapy, have proved to be very effective in treating T2D. We provide here an overview of current successes, some drawbacks and future possibilities for GPCR-based T2D therapies.",

author = "Persaud, {Shanta J.} and Olaniru, {Oladapo E.} and Patricio Atanes",

year = "2021",

doi = "10.1042/bio_2021_108",

language = "English",

volume = "43",

pages = "28--33",

journal = "Biochemist",

issn = "0954-982X",

publisher = "Portland Press Ltd.",

number = "2",

}

TY - JOUR

T1 - Targeting islet G-protein-coupled receptors for type 2 diabetes therapy

AU - Persaud, Shanta J.

AU - Olaniru, Oladapo E.

AU - Atanes, Patricio

PY - 2021

Y1 - 2021

N2 - The majority of people with diabetes have type 2 diabetes (T2D), where hyperglycaemia occurs because the islet p-cells are unable to secrete enough insulin, usually in the context of insulin resistance that arises because of fat mass expansion. There are a range of pharmacotherapies in current use to treat T2D and pharmaceutical companies are actively engaged in the development of novel therapies for better glucose control. Ligands that target G-protein-coupled receptors (GPCRs) are obvious candidates because they are used successfully for a wide range of disorders and GLP-1 receptor agonists, which are a relatively recent class of diabetes therapy, have proved to be very effective in treating T2D. We provide here an overview of current successes, some drawbacks and future possibilities for GPCR-based T2D therapies.

AB - The majority of people with diabetes have type 2 diabetes (T2D), where hyperglycaemia occurs because the islet p-cells are unable to secrete enough insulin, usually in the context of insulin resistance that arises because of fat mass expansion. There are a range of pharmacotherapies in current use to treat T2D and pharmaceutical companies are actively engaged in the development of novel therapies for better glucose control. Ligands that target G-protein-coupled receptors (GPCRs) are obvious candidates because they are used successfully for a wide range of disorders and GLP-1 receptor agonists, which are a relatively recent class of diabetes therapy, have proved to be very effective in treating T2D. We provide here an overview of current successes, some drawbacks and future possibilities for GPCR-based T2D therapies.

UR - http://www.scopus.com/inward/record.url?scp=85104709016&partnerID=8YFLogxK

U2 - 10.1042/bio_2021_108

DO - 10.1042/bio_2021_108

M3 - Article

AN - SCOPUS:85104709016

SN - 0954-982X

VL - 43

SP - 28

EP - 33

JO - Biochemist

JF - Biochemist

IS - 2

ER -

Targeting islet G-protein-coupled receptors for type 2 diabetes therapy

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this